author-photo

Laurence Skillern

Astellas Pharma

4

Papers

34

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.

2020 Menopause
Show All
- Source
- Cite
- Save
Citations (20)
Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA).

2020 Menopause
Show All
- Source
- Cite
- Save
Citations (8)
OR33-6 The Neurokinin 3 Receptor Antagonist, Fezolinetant, Is Effective in Treatment of Menopausal Vasomotor Symptoms: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study

2019 Journal of the Endocrine Society
Show All
- Source
- Cite
- Save
Citations (3)